Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug 19.
doi: 10.1111/hepr.14101. Online ahead of print.

Trajectories of hepatic steatosis and incidence of cardiovascular disease over a 29-year follow-up

Ming-Whei Yu  1 , Wan-Jung Wu  1 , Chih-Lin Lin  2 , Chun-Jen Liu  3   4   5 , Wei-Ya Peng  1 , Pin-Yu Huang  1 , Yi-Wen Huang  6 , Jui-Ting Hu  7 , Hung-Chuen Chang  8   9 , Jyh-Ming Liou  3   10   11
Affiliations

Trajectories of hepatic steatosis and incidence of cardiovascular disease over a 29-year follow-up

Ming-Whei Yu et al. Hepatol Res. .

Abstract

Aim: To examine the dynamic change in hepatic steatosis status during repeated assessments over time, and its potential impact on the risk of developing cardiovascular disease (CVD).

Methods: We assessed trajectories of hepatic steatosis and other metabolic disorders in 3134 middle-aged adults undergoing longitudinal assessment of ultrasonography during a pre-baseline period (1993-2009) in a population-based cohort study of liver health. Subsequently, we determined the association of hepatic steatosis trajectories with the incidence of CVD among 2185 CVD-free individuals, followed until 2021. Metabolic risk factors and cardiovascular events (including coronary heart disease and stroke) were determined through medical examination and linkage with nationwide health databases.

Results: We identified three discrete trajectories of hepatic steatosis according to changing pattern over time through group-based trajectory modeling: "stable, non-steatosis" (n = 1298), "intermittent" (n = 921), and "persistent steatosis" (n = 915). During the pre-baseline period, hepatic steatosis trajectories were associated with trajectories of developing diabetes and hypertension, and persistent steatosis (vs. other trajectories) was associated with higher risks and rapidly progressive disease patterns. At a median 13.6 years of follow-up, 629 CVD events occurred. A persistent (vs. non-steatosis: HR 1.44, 95% CI 1.17-1.76), but not intermittent, steatosis pattern predicted the future risk of CVD, after adjustment for age, sex, smoking, and obesity. This association was independent of genetic background, and remained after accounting for pre-baseline body-mass index, other cardiometabolic risk factors, Framingham risk score, medications, and hepatic fibrosis score.

Conclusions: The persistence of hepatic steatosis is associated with trajectories of metabolic disorder development and increased risk of CVD. These data have important implications for practice and further research.

Keywords: cardiovascular disease; coronary heart disease; hepatic steatosis; metabolic dysfunction‐associated steatotic liver disease; stroke.

PubMed Disclaimer

References

REFERENCES

    1. Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77(4):1335–1347. https://doi.org/10.1097/hep.0000000000000004
    1. Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966–1986. https://doi.org/10.1097/hep.0000000000000520
    1. Quek J, Chan KE, Wong ZY, Tan C, Tan B, Lim WH, et al. Global prevalence of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta‐analysis. Lancet Gastroenterol Hepatol. 2023;8(1):20–30. https://doi.org/10.1016/s2468‐1253(22)00317‐x
    1. Mantovani A, Csermely A, Petracca G, Beatrice G, Corey KE, Simon TG, et al. Non‐alcoholic fatty liver disease and risk of fatal and non‐fatal cardiovascular events: an updated systematic review and meta‐analysis. Lancet Gastroenterol Hepatol. 2021;6(11):903–913. https://doi.org/10.1016/s2468‐1253(21)00308‐3
    1. Meyersohn NM, Mayrhofer T, Corey KE, Bittner DO, Staziaki PV, Szilveszter B, et al. Association of hepatic steatosis with major adverse cardiovascular events, independent of coronary artery disease. Clin Gastroenterol Hepatol. 2021;19(7):1480–1488. https://doi.org/10.1016/j.cgh.2020.07.030

LinkOut - more resources